Gilead Sciences, Inc. $GILD Shares Acquired by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 90.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,108 shares of the biopharmaceutical company’s stock after purchasing an additional 47,457 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Gilead Sciences were worth $11,112,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GILD. GoalVest Advisory LLC increased its stake in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the third quarter valued at approximately $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the second quarter worth approximately $27,000. Putney Financial Group LLC increased its position in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences during the second quarter worth approximately $30,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GILD has been the topic of several recent research reports. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. TD Cowen raised their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. UBS Group reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Thursday, January 15th. Sanford C. Bernstein set a $135.00 price objective on shares of Gilead Sciences and gave the company an “outperform” rating in a report on Monday, December 29th. Finally, Citigroup raised their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.52.

Gilead Sciences Price Performance

Shares of GILD stock opened at $135.93 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The company has a market capitalization of $168.65 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 0.69 and a beta of 0.33. The firm’s 50-day moving average is $123.98 and its two-hundred day moving average is $118.62. Gilead Sciences, Inc. has a 12 month low of $92.26 and a 12 month high of $136.30.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.3%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Insider Activity

In related news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the transaction, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 141,757 shares of company stock worth $17,569,112 in the last quarter. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.